Basal Ganglia Pathophysiology
161 – 170 of 192
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective.
(
- Contribution to journal › Article
-
Mark
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
(
- Contribution to journal › Article
-
Mark
Orexin loss in Huntington's disease.
(
- Contribution to journal › Article
-
Mark
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
(
- Contribution to journal › Article
-
Mark
Chapte B7 - Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease
2005) p.193-208(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- 2004
-
Mark
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
(
- Contribution to journal › Article
-
Mark
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
(
- Contribution to journal › Article
-
Mark
Modelling parkinsonian akinesia and dyskinesia in dopamine depleted rodents
2004)(
- Thesis › Doctoral thesis (compilation)